Check4Cancer & Alula Launch a Partnership to Manage Cardiovascular and Cancer Risk.

13th December 2024 - The unique combination of MyCancerRisk© from Check4Cancer and VivaScore® from Alula Technologies creates a digitally enabled, comprehensive solution for assessing, monitoring, and understanding both cancer and cardiovascular disease (CVD) risks, the top two causes of global insurance claims in 2023. Together, these offerings empower organisations and individuals to take proactive steps toward achieving better health outcomes.

Professor Wishart, CEO & Chief Medical Officer at Check4Cancer, commented, “At Check4Cancer, our fundamental aim is to promote cancer prevention and early cancer detection. Our MyCancerRisk© platform identifies employees at higher risk for six common cancers using an online, tailored questionnaire. Those at higher risk are directed to risk reduction and cancer screening and, ROI can be calculated at 5 or 10 years for the insurer or company”.

Prof Gordon Wishart went on to say that, “By partnering with Alula, we can jointly tackle the top two causes of global claims by raising awareness of the risks and symptoms of both cancer and CVD and, by promoting targeted prevention strategies”.

Simon Spurr, Managing Director at Alula Health, “With nearly 8 million people living with cardiovascular disease in the UK – accounting for around 25% of all deaths – it represents a growing challenge for the healthcare system, employers, and insurers. Evidence shows that preventative health checks, combined with behavioural changes, can significantly reduce its prevalence. Our innovative VivaScore solution leverages advanced data analytics to provide users with a clear understanding of their health risks, empowering them to make impactful behavioural changes through an engaging and user-friendly experience. We are excited to partner with Check4Cancer to address two of the largest drivers of insurance claims, delivering better health outcomes together.”

This proactive and joint approach to cancer risk, and CVD risk, management will foster early disease detection leading to better outcomes, improved survival rates, enhanced employee wellbeing and substantial financial savings by reducing workplace claims costs. 
For all press enquiries, please contact:

Alula
Nelson Camara, Marketing Executive
E: Nelson.Camara@alulatechnologies.com 
T: +44 203 205 7173

Check4Cancer
Beth Rankine, Marketing Consultant
E: beth.rankine@check4cancer.com
T: 07484 753009

About Alula
Alula Technologies is a global technology group headquartered in London, UK. Alula provides innovative solutions to clients in insurance, employee benefits, and healthcare, leveraging AI and machine learning to enhance risk understanding and improve customer and employee experiences. Alula’s flagship product, VivaScore, combines health and wellness data to offer a comprehensive view of an individual’s health, driving more accurate and faster decision-making processes.

About Check4Cancer
Check4Cancer provides comprehensive cancer detection services, combining clinical expertise with cutting-edge technology to offer personalised and effective cancer risk assessment, screening and diagnostic pathways. From corporate wellness programs to AI-driven skin cancer detection tools, Check4Cancer is dedicated to improving outcomes through early detection.